Completed PHASE2 INTERVENTIONAL NCT00004033

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

Phase II Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally in Patients With Malignant Pleural Mesothelioma

Sponsor: NYU Langone Health

Conditions Malignant Mesothelioma

Interventions liposomal NDDP therapeutic thoracoscopy

Updated 6 times since 2017 Last updated: Mar 25, 2011 Started: Sep 30, 1998 Primary completion: May 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Malignant Mesothelioma, this trial is completed. The trial is conducted by NYU Langone Health and has accumulated 6 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jun 2019 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NYU Langone Health
National Cancer Institute (NCI)

Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States
• New York, United States